Catalent Inc. (CTLT)

50.42
NYSE : Health Technology
Prev Close 49.11
Day Low/High 49.10 / 50.44
52 Wk Low/High 29.23 / 58.38
Avg Volume 745.80K
Exchange NYSE
Shares Outstanding 146.31M
Market Cap 7.19B
EPS 0.90
P/E Ratio 50.63
Div & Yield N.A. (N.A)

Latest News

Coca-Cola, Starbucks, Nokia: 'Mad Money' Lightning Round

Coca-Cola, Starbucks, Nokia: 'Mad Money' Lightning Round

Jim Cramer weighs in on Coca-Cola, Starbucks, Nokia, Marvell Technology, Arbor Trust Realty, CrowdStrike, Proofpoint, Catalent, Charles River Labs.

Zydis® ODT Fast Dissolve Technology By Catalent (Photo: Business Wire)

Zydis® ODT Fast Dissolve Technology By Catalent (Photo: Business Wire)

Cycle Pharmaceuticals Ltd (Cycle) is pleased to announce that it has signed an agreement with Catalent, Inc.

Catalent, Inc. Announces First Quarter Fiscal Year 2020 Earnings Conference Webcast

Catalent, Inc. Announces First Quarter Fiscal Year 2020 Earnings Conference Webcast

Catalent, Inc. (NYSE: CTLT) ("Catalent"), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, today announced that it will release financial results for the first...

Catalent, Inc. Reports Fourth Quarter Fiscal 2019 Results

Catalent, Inc. Reports Fourth Quarter Fiscal 2019 Results

Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced financial results for the fourth quarter of fiscal year 2019, which...

Catalent, Inc. Announces Fourth Quarter Fiscal Year 2019 Earnings Conference Webcast

Catalent, Inc. Announces Fourth Quarter Fiscal Year 2019 Earnings Conference Webcast

Catalent, Inc. (NYSE: CTLT) ("Catalent"), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, today announced that it will release financial results for the fourth...

Catalent Extends Global Commercial Spray Drying Capabilities In Europe

Catalent Extends Global Commercial Spray Drying Capabilities In Europe

Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, and development and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced that it has significantly expanded...

Catalent Announces Pricing Of Private Offering Of Senior Unsecured Notes Due 2027

Catalent Announces Pricing Of Private Offering Of Senior Unsecured Notes Due 2027

Catalent, Inc. ("Catalent") (NYSE: CTLT), the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that its wholly owned subsidiary, Catalent...

Catalent Announces Launch Of Private Offering Of $500 Million Of Senior Unsecured Notes Due 2027

Catalent Announces Launch Of Private Offering Of $500 Million Of Senior Unsecured Notes Due 2027

Catalent, Inc. ("Catalent") (NYSE: CTLT), the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that its wholly owned subsidiary, Catalent...

Catalent To Purchase Bristol-Myers Squibb Manufacturing Facility In Anagni, Italy

Catalent To Purchase Bristol-Myers Squibb Manufacturing Facility In Anagni, Italy

Bristol-Myers Squibb Company (NYSE:BMY) and Catalent, Inc. (NYSE: CTLT), today announced that Catalent has agreed to purchase Bristol-Myers Squibb's oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy.

Catalent, Inc. To Present At The Jefferies Healthcare Conference

Catalent, Inc. To Present At The Jefferies Healthcare Conference

Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Wetteny Joseph, Senior Vice President & Chief Financial Officer,...

Catalent Completes Acquisition Of Gene Therapy Leader Paragon Bioservices, Inc. For $1.2 Billion

Catalent Completes Acquisition Of Gene Therapy Leader Paragon Bioservices, Inc. For $1.2 Billion

Catalent, Inc. (NYSE:CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has completed the $1.

Catalent, Inc. Reports Third Quarter Fiscal 2019 Results

Catalent, Inc. Reports Third Quarter Fiscal 2019 Results

Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced financial results for the third quarter of fiscal year 2019, which...

Catalent to Buy Paragon Bioservices for $1.2 Billion

Catalent to Buy Paragon Bioservices for $1.2 Billion

Drugmaker Catalent reaches an agreement to buy closely held Paragon Bioservices, the latest deal in the burgeoning gene-therapy treatment space.

Catalent To Acquire Gene Therapy Leader Paragon Bioservices, Inc. For $1.2 Billion

Catalent To Acquire Gene Therapy Leader Paragon Bioservices, Inc. For $1.2 Billion

Catalent, Inc. (NYSE:CTLT), the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, and Paragon Bioservices, Inc.

Catalent, Inc. Announces Third Quarter Fiscal Year 2019 Earnings Conference Webcast

Catalent, Inc. Announces Third Quarter Fiscal Year 2019 Earnings Conference Webcast

Catalent, Inc. (NYSE: CTLT) ("Catalent"), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, today announced that it will release financial results for the third...

Catalent, Inc. To Present At The Barclays Global Healthcare Conference

Catalent, Inc. To Present At The Barclays Global Healthcare Conference

Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Wetteny Joseph, Senior Vice President & Chief Financial Officer,...

Catalent Names Alessandro Maselli President And Chief Operating Officer

Catalent Names Alessandro Maselli President And Chief Operating Officer

Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Senior Vice President, Global Operations Alessandro Maselli has...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AXE, CTLT, FTI, INSW, LAZ, MAS, MLI, NCLH, PCMI, PDLI, TTWO, UFS, VIAV Downgrades: CIA, DLR, I, LIVE, MKL, SNHY Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Catalent, Inc. Reports Second Quarter Fiscal 2019 Results

Catalent, Inc. Reports Second Quarter Fiscal 2019 Results

Catalent, Inc. (NYSE:CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced financial results for the second quarter of fiscal year 2019, which...

Catalent, Inc. Announces Second Quarter Fiscal Year 2019 Earnings Conference Webcast

Catalent, Inc. Announces Second Quarter Fiscal Year 2019 Earnings Conference Webcast

Catalent, Inc. (NYSE: CTLT) ("Catalent"), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, today announced that it will release financial results for the second...

Catalent Invests $200 Million To Expand Biologics Capacity And Capabilities

Catalent Invests $200 Million To Expand Biologics Capacity And Capabilities

Catalent, Inc. (NYSE:CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced it has commenced a $200 million capital investment in its Biologics...

Catalent, Inc. To Present At The 37th Annual J.P. Morgan Health Care Conference

Catalent, Inc. To Present At The 37th Annual J.P. Morgan Health Care Conference

Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that John Chiminski, Chairman & Chief Executive Officer, will present...

First Week Of CTLT July 2019 Options Trading

First Week Of CTLT July 2019 Options Trading

Investors in Catalent Inc saw new options become available this week, for the July 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

CTLT: Insiders Vs. Shorts

CTLT: Insiders Vs. Shorts

The most recent short interest data was recently released for the 10/31/2018 settlement date, and Catalent Inc is one of the most shorted stocks of the Russell 3000, based on 5.70 "days to cover" versus the median component at 4.44. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMRC, ERA, HCI, MRO, PAA, PRPH, QDEL, SRE, TSLA Downgrades: ALRM, APEI, ASH, AVNS, CHUY, CTLT, HCLP, KE, MB, NKTR, NTB, TTWO Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Catalent, Inc. Reports First Quarter Fiscal 2019 Results

Catalent, Inc. Reports First Quarter Fiscal 2019 Results

Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced financial results for the first quarter of fiscal year 2019, which...

Catalent, Inc. To Present At Three Upcoming Investor Conferences

Catalent, Inc. To Present At Three Upcoming Investor Conferences

Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Wetteny Joseph, Senior Vice President & Chief Financial Officer,...

Catalent, Inc. Announces First Quarter Fiscal Year 2019 Earnings Conference Webcast

Catalent, Inc. Announces First Quarter Fiscal Year 2019 Earnings Conference Webcast

Catalent, Inc. (NYSE: CTLT) ("Catalent"), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, today announced that it will release financial results for the first...

TheStreet Quant Rating: B- (Buy)